Topic · 60 episodes
Health
Health in 2024 is being reshaped by precision medicine across several fronts. Onpode's coverage spans gene therapy for hereditary angioedema, a non-hormonal menopause treatment reducing hot flashes and mood symptoms, an oral GLP-1 pill delivering meaningful weight loss and blood sugar control, and the FDA's first targeted approval for PTEN-deficient prostate cancer. The through-line: treatments engineered for defined patient populations.
Frequently asked
What are the Phase 3 results for Intellia's lonvo-z gene therapy?
Intellia's lonvo-z posted strong Phase 3 results for hereditary angioedema treatment. The data marked a significant milestone for gene therapy in this rare genetic condition, suggesting lonvo-z could offer a durable intervention for patients managing hereditary angioedema.
Is there a menopause treatment that works without hormones?
A non-hormonal menopause treatment has shown in trials that it can reduce hot flashes, anxiety, and depression without the risks associated with hormone replacement therapy. This offers a meaningful alternative for people who cannot or prefer not to use HRT.
Can a pill replace injectable GLP-1 drugs for diabetes and weight loss?
A new GLP-1 diabetes pill has achieved significant weight loss and blood sugar control in clinical trials, suggesting an effective oral pill could be a viable alternative to injectable GLP-1 therapies for patients managing type 2 diabetes and obesity.
What is AstraZeneca's Truqap and what did the FDA approve it for?
AstraZeneca's Truqap received FDA approval as the first and only targeted treatment for PTEN-deficient prostate cancer. This approval represents a precision oncology advance, giving clinicians a specifically indicated option for a prostate cancer subgroup defined by PTEN loss.
Episodes
An experimental pill paired with chemotherapy shrank tumors in most advanced pancreatic cancer patients—early phase results at Barcelona conferenceDaraxonrasib, an experimental pill targeting KRAS, shrank tumors in 60.7% of 61 first-line metastatic pancreatic cancer patients when added to standard chemotherapy, with a median progression-free survival of 12.8 months. The trial has no control arm, so the randomized RASolute 303 trial is needed to confirm whether the drug itself drives the benefit.
A pill taken before breakfast slashed bad cholesterol by nearly two-thirds in patients already on statinsEnlicitide (Lipfendra), FDA-approved July 16, 2026, is the first oral PCSK9 inhibitor — a once-daily pill that cut LDL cholesterol by up to 65% in statin users during Merck's Phase 3 CORALreef trial. No cardiovascular outcomes data yet exists; that trial is ongoing.
A 30,000-person review reveals three antidepressants may beat Prozac—but long-term depression treatment remains largely unknownA recent Lancet Psychiatry network meta-analysis of 115 trials and 30,428 adults found escitalopram, duloxetine, and agomelatine each showed higher sustained response than fluoxetine (Prozac). Lead author Dr. Eric Ruhé advises patients already stable on fluoxetine not to switch — findings are most relevant for people starting treatment.
FDA approved neladalkib for lung cancer, Sunharbor for stroke prevention, Sogroya for Turner syndrome, and more—all within daysThe FDA approved neladalkib (Nelkarmi) for ALK-positive lung cancer on November 17 and Sogroya for Turner syndrome on November 20, 2026. Neladalkib showed a 49% response rate after alectinib; Sogroya's weekly schedule grew 8.9 cm/year versus 9.7 cm/year daily—a gap the trial was too small to resolve. Both neladalkib and Sogroya still await confirmatory data.
Why belief changes biology — the neural mechanisms behind expectation effects
Livsayis (cemdisiran) is the second new MG drug approved this week—but its siRNA mechanism is entirely novel
Sunharbo cuts post-stroke ischemia risk 26%—but clinicians weigh bleeding trade-offs for high-risk patients
SELLAS's leukemia vaccine cut death risk 41% in Phase 3—but won't file with FDA until 2027
Prevention saves lives but treatment sells drugs — the economic incentive mismatch
The dose-response curve and why all drugs are toxins at the wrong concentration
From anecdotes to RCTs — why some medical evidence is stronger than others
The structural reason most published medical findings don't replicate — and what journals incentivize
Why randomization and blinding are the only way to separate drug effect from expectation
Genetic variation in drug metabolism — why one person's cure is another's overdose
FDA approved nanobody therapy for myasthenia gravis, pimicotinib for tenosynovial tumors, and a stent for carotid intervention—each addressing unmet needs in rare disease
The FDA just issued guidance for 'plug and play' gene therapies—a shift toward modular, faster manufacturing that could unlock rare-disease treatments
AstraZeneca, Pfizer, and Astellas won FDA approval for a combo therapy with 42% lower death risk in bladder cancer—challenging surgery as standard
FDA just approved Bayer's Sunharbo—a daily pill cutting repeat stroke risk by 26% through a novel clotting pathway
The placebo effect isn't psychology — it's real physiology working through expectation
An FDA-approved pancreatic cancer drug is now showing promise in early-stage lung cancer trials—expanding its therapeutic reach
Every participant in a major NIH study of 100,000 Americans carried gene variants that alter how their bodies process drugs
FDA reportedly abandons Commissioner's priority voucher program and fast-track drug review initiative—what it means for drug developers
FDA grants first-ever Breakthrough Therapy status to Cu-64 SAR-bisPSMA for prostate cancer recurrence detection
The screening paradox: detecting disease vs preventing harm in asymptomatic populations
EFF documents expose new problems emerging in Medicare's ongoing AI pilot program
A new psychedelic nasal spray is showing early promise in patients with treatment-resistant depression
FDA greenlit four oncology combos this week, but nivolumab-chemo just missed its bladder cancer goals
Lilly's retatrutide just doubled Ozempic's weight loss and cut A1C more in direct comparison
New research says two drinks a day might be far riskier than doctors have long advised
How randomization removes bias that observational data can never eliminateRandomization eliminates confounding by making treatment assignment independent of every patient characteristic — measured or not. The HRT case shows why this matters: observational studies of millions of women pointed to heart protection, but a single RCT of 16,000 women found the opposite, because the observational data confused health-conscious behavior with a treatment effect.
The gap between measurable markers and actual health outcomesUp to 50% of heart attacks occur in people with normal cholesterol readings. Only about 15% of women classified as metabolically healthy at normal weight stayed that way after 30 years. Standard biomarkers measure population-level correlations — they cannot reliably predict individual health outcomes, a structural gap medicine has yet to resolve.
Why public health invests in prevention even though treatment feels more urgentPreventing cholera costs $11 per life-year saved; treating the resulting diarrheal disease costs $1,062 — 96 times more. Yet governments fund treatment at roughly ten times the rate of prevention. The gap persists not from ignorance but because the entities that pay for prevention never capture the savings that prevention generates.
The central paradox: how the immune system learns friend from foeHealthy people carry autoreactive lymphocytes because the thymus and bone marrow structurally cannot screen every self-antigen. AIRE expands the thymus's preview of peripheral tissues, Tregs suppress what escapes, yet no tool can tell whether any individual's peripheral tolerance is stable or about to fail.
Why identifying causative agents became the foundation of disease controlJohn Snow removed the Broad Street pump handle in 1854 and ended a cholera outbreak — thirty years before germ theory was accepted. The shift from miasma to germ theory didn't change which interventions worked; it changed the precision with which medicine could target them, enabling specific pathogens like the tuberculosis bacillus to be isolated and named.
How threshold effects in pharmacology explain why more drug isn't always betterDrug dose-response curves follow a threshold, steep climb, and plateau — not a straight line. The therapeutic window sits between minimum effective concentration and the toxicity threshold, and for narrow-index drugs like warfarin or digoxin, that margin can be as thin as 100 milligrams per square meter, as floxuridine trials demonstrated.
Peptides are everywhere now; here are 4 red flags and the one truth behind the hypeFDA staff scientists concluded that BPC-157, KPV, TB-500, and other compounded peptides lack adequate safety evidence — yet an advisory panel narrowly voted to ease compounding restrictions on the same compounds in 2026. The one peptide category with demonstrated efficacy is GLP-1 receptor agonists like semaglutide, which completed rigorous clinical trials.
FDA-approved gene therapy gives deaf children normal hearing in weeks — here's how it worksOtarmeni, Regeneron's FDA-approved gene therapy for genetic deafness, received accelerated approval on April 23, 2026 — the first of its kind in the U.S. In the pivotal trial, only 5 of 12 children (42%) reached normal hearing range at 48 weeks, a figure obscured by the widely reported 80% improvement headline.
The FDA approved Avacopan despite manipulated trial data linked to 8 deaths — a major integrity failureAvacopan (Tavneos) received FDA approval in 2021 after ChemoCentryx personnel unblinded to trial arms re-adjudicated nine patients' endpoints in November 2019, flipping a non-significant ADVOCATE trial result. Separately, the FDA documented 76 liver-injury cases, 54 hospitalizations, and 8 deaths in post-market use across 25,000 patient-years.
FDA just approved Eli Lilly's weight-loss pill — a major pharma breakthrough todayEli Lilly's orforglipron (Foundayo) was FDA-approved April 1st for chronic weight management in adults with obesity, but it entered a market Novo Nordisk's oral Wegovy had already defined — accumulating over 600,000 U.S. prescriptions by the time Foundayo launched. Insurance coverage remains unresolved; out-of-pocket cost runs $149–$349 monthly.
The neurobiology of expectation: why belief changes measurable physiologyPlacebo effects produce measurable physiology: dopamine in the nucleus accumbens rises 15–20% on pain-relief expectation alone, triggering real endorphin release before any pill dissolves. Yet a landmark review by Hróbjartsson and Gøtzsche found placebos don't reliably beat no treatment on objective outcomes — the brain modulates pain signals, not tissue damage.
Antibiotic-resistant sexually transmitted diarrhea is surging in the US — a growing public health crisisExtensively drug-resistant Shigella — a gut bug now spreading sexually through oral-anal contact — has surged at UCLA from one case per year in 2022 to roughly one per month in 2026. Nationally, XDR strains rose from 0% to 8.5% of isolates by 2023, with over one-third of XDR patients hospitalized and no replacement antibiotic class identified.
A new 12-week randomized trial shows aerobic and strength exercise improves metabolic health and fat mass even without scale weight droppingA 12-week randomized controlled trial published in Frontiers in Public Health (August 2026, lead author Jineng Chen) found that combined aerobic and resistance training reduced fat mass and increased strength in overweight adults with cardiometabolic risk factors — while total scale weight stayed essentially flat. The authors themselves called the effects modest.
Scientists found an injection that reduces dangerous belly fat independent of overall weight — raising questions about what matters mostCBL-514, a targeted injection tested by Caliway Biopharmaceuticals, reduced visceral fat by 12.01% in a phase 2 trial — while the placebo group gained 5.68% — without overall weight loss. Presented at EASD Milan (September 28–October 2, 2026) and announced to the press on October 13, the data raises a deeper question: should clinical medicine stop using the scale to define metabolic risk?
FDA just approved a new drug specifically for herpes simplex virus lesions in adultsThe FDA approved pritelivir (Hovilpri), the first drug in roughly 30 years with a novel HSV mechanism, specifically for immunocompromised adults whose lesions failed acyclovir, valacyclovir, and famciclovir. The Phase 3 PRIOH-1 trial showed 63% complete lesion healing by day 28 versus 34% on comparator.
Standard vs accelerated approval: how urgency changes evidence requirementsFDA Accelerated Approval is the only expedited pathway that actually lowers the evidentiary bar — replacing confirmed clinical outcomes with surrogate endpoints like tumor shrinkage. Fast Track, Breakthrough Therapy, and Priority Review leave the standard unchanged. Lartruvo's 2016 approval on 133 patients, later contradicted by a 509-patient confirmatory trial, illustrates the real cost of that tradeoff.
Why health systems reward treating disease but not preventing itAccountable Care Organizations saved Medicare $12 billion over 14 years — roughly $0.86 per American per year — while fee-for-service still dominates and prevention receives under 2% of the U.S. healthcare dollar. The core problem isn't misaligned incentives alone: it's that prevention's financial benefits land in different pockets than those who pay for it.
From miasma to microbes: how identifying infectious agents rewired disease thinkingMiasma theory was wrong about mechanism yet drove sanitation that interrupted Vibrio cholerae transmission and saved lives. John Snow removed the Broad Street pump handle in 1854 without knowing the pathogen. Koch's postulates, formalized in 1876, failed almost immediately for viruses and conditional pathogens — yet were taught as gospel for nearly a century.
The biomarker paradox: why lowering a risk factor doesn't always prevent diseaseLowering a biomarker does not always prevent disease. Rosiglitazone durably lowered blood sugar yet increased heart attack risk; torcetrapib raised HDL and lowered LDL across 15,000 patients yet raised mortality. A drug that moves a measurement has only proven it can move that number — not that it addresses the disease mechanism.
How dose-response curves explain why medicine and poison are dose apartDose-response curves explain why aspirin relieves pain at 500 mg but becomes toxic above roughly 150 mg per kilogram of body weight — same molecule, different dose. Paracelsus established this principle in the 1500s; today, the EC50 metric and therapeutic drug monitoring translate it into clinical practice, but individual variation means population averages often mislead.
Why orphan drugs move fast but common diseases move slow — the incentive structureMore than half of recent FDA approvals are orphan drugs — yet roughly 9,000 of 10,000 rare diseases still have no approved treatment. The Orphan Drug Act of 1983 corrected a real market failure, but its incentives (seven-year exclusivity, tax credits, fee waivers) select for commercially tractable diseases, not greatest unmet need.
Why health systems excel at saving acute crises but struggle with lifelong conditions90% of U.S. healthcare spending — $5.3 trillion annually — goes to chronic and mental health conditions, yet the system is built to reward acute interventions. Prevention generates no billing code, no discharge note, and no attributable outcome, so clinicians and drug developers alike are structurally pushed away from the conditions causing the most harm.
Why vaccines protect people who don't get vaccinated — the math of herd immunityHerd immunity protects unvaccinated individuals by breaking transmission chains once enough people are immune. The required threshold is calculated as 1 − 1/R₀: measles needs 92–95% coverage because its R₀ reaches 18, while seasonal flu's threshold can fall below 30% because its R₀ barely exceeds 1.
Why placebos change pain signals — the neurobiology of expectationPlacebos relieve pain through measurable neurobiology: anticipatory expectation triggers real endorphin release via the same opioid pathways as morphine, and fMRI shows the anterior cingulate cortex going quiet. Even in open-label trials — where patients know the pill is inert — the effect holds, because conditioned nervous-system reflexes run below conscious thought.
Novartis pelacarsen lowered Lp(a) levels in 8,323 patients—but didn't reduce cardiovascular eventsPelacarsen reduced Lp(a) levels by up to 80% in 8,323 patients with established cardiovascular disease — but failed to reduce heart attacks or strokes compared to placebo in the Lp(a)HORIZON Phase 3 trial, raising the question of whether lowering Lp(a) late in disease is simply too late.
New screening advances target the 1-in-8 lifetime risk of prostate cancer diagnosisProstate cancer carries a 1-in-8 lifetime diagnosis risk for men in the U.S., with 333,830 new cases projected in 2026. PSA-based screening prevents roughly 2 deaths per 1,000 men screened, but the central challenge is distinguishing aggressive cancers from indolent ones before biopsy — the goal driving mpMRI, ClarityDX, and updated 2026 AUA/SUO guidelines.
Bill Ackman's daughter regained sight using first-of-its-kind cell transfer from her own legIn May 2026, Lucy Ackman, 26, became the first person to receive mitochondria transplanted into human eyes — cells extracted from her own leg muscle and injected into both eyes at Mount Sinai. She perceived shapes and shadows for four weeks before the effect faded. The case remains an unreviewed preprint as of August 10, 2026.
FDA just cleared three breakthrough drugs—for rare neurological disease, ADHD, and breast cancerThe FDA approved three breakthrough drugs in 48 hours — Zanvastro (zilganersen) for Alexander disease, the first-ever disease-modifying treatment for a condition affecting fewer than one in a million people, trialed in just 54 patients; Simtriyo for ADHD via a new mechanism; and Etcamah for breast cancer, the first cancer drug approved using liquid biopsy data alone.
How randomization breaks the causation-correlation problem in medical evidenceRandomization in medical trials breaks the causation-correlation problem by distributing unknown confounders equally across groups — a method traced to Austin Bradford Hill's 1948 MRC streptomycin trial and Ronald Fisher's agricultural experiments. But the guarantee only holds when participants comply and the trial population matches the real-world patient.
Why medicine excels at antibiotics but struggles with obesity and diabetesInfectious disease mortality in the United States fell from 797 to 36 per 100,000 between 1900 and 1980 — a collapse medicine largely credited to drugs. That attribution shaped an entire institutional logic — one pathogen, one drug, one endpoint — that medicine now applies to obesity and type 2 diabetes, diseases with no single pathogen and no moment of cure.
Before germ theory, medicine was intuition — how Pasteur and Koch changed everythingGerm theory won in the mid-1800s not because it was the most complete truth, but because it was the most solvable story medicine had ever had. Koch's postulates identified one microbe per disease by 1883 — yet today 70% of disease burden in developed countries is chronic and noncommunicable, with no pathogen to blame.